ArticlePharmaceuticals (Basel, Switzerland)2025

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Ekaterina I Alexeeva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.